EUR 27.0
(-0.37%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 590.2 Million EUR | -25.24% |
2022 | 789.49 Million EUR | 2.44% |
2021 | 770.7 Million EUR | -1.42% |
2020 | 781.82 Million EUR | 2.29% |
2019 | 764.28 Million EUR | -0.36% |
2018 | 767.07 Million EUR | -4.16% |
2017 | 800.4 Million EUR | 6.01% |
2016 | 755.03 Million EUR | 8.57% |
2015 | 695.44 Million EUR | 3.87% |
2014 | 669.55 Million EUR | 0.29% |
2013 | 667.58 Million EUR | 15.24% |
2012 | 579.28 Million EUR | -1.42% |
2011 | 587.6 Million EUR | 5.24% |
2010 | 558.33 Million EUR | 6.98% |
2009 | 521.93 Million EUR | 12.65% |
2008 | 463.34 Million EUR | 8.16% |
2007 | 428.39 Million EUR | 3.96% |
2006 | 412.05 Million EUR | -3.56% |
2005 | 427.25 Million EUR | 57.65% |
2004 | 271.01 Million EUR | 9.29% |
2003 | 247.97 Million EUR | 7.47% |
2002 | 230.72 Million EUR | 12.08% |
2001 | 205.86 Million EUR | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 557.65 Million EUR | 0.0% |
2023 Q2 | 752.77 Million EUR | 0.0% |
2023 Q4 | 590.2 Million EUR | 0.0% |
2023 FY | 590.2 Million EUR | -25.24% |
2022 FY | 789.49 Million EUR | 2.44% |
2022 Q4 | 789.49 Million EUR | 0.0% |
2022 Q2 | 770.63 Million EUR | 0.0% |
2021 Q4 | 770.7 Million EUR | 0.0% |
2021 Q2 | 734.22 Million EUR | 0.0% |
2021 FY | 770.7 Million EUR | -1.42% |
2020 FY | 781.82 Million EUR | 2.29% |
2020 Q2 | 757.69 Million EUR | 0.0% |
2020 Q4 | 781.82 Million EUR | 0.0% |
2019 Q2 | 725.69 Million EUR | 0.0% |
2019 Q4 | 764.28 Million EUR | 0.0% |
2019 FY | 764.28 Million EUR | -0.36% |
2018 Q2 | 708.47 Million EUR | 0.0% |
2018 Q4 | 767.07 Million EUR | 0.0% |
2018 FY | 767.07 Million EUR | -4.16% |
2017 Q4 | 800.4 Million EUR | 0.0% |
2017 FY | 800.4 Million EUR | 6.01% |
2017 Q2 | 725.23 Million EUR | 0.0% |
2016 FY | 755.03 Million EUR | 8.57% |
2016 Q4 | 755.03 Million EUR | 0.0% |
2016 Q2 | 674.41 Million EUR | 0.0% |
2015 Q4 | 695.44 Million EUR | 0.0% |
2015 Q2 | 627.11 Million EUR | 0.0% |
2015 FY | 695.44 Million EUR | 3.87% |
2014 Q4 | 669.55 Million EUR | 0.0% |
2014 FY | 669.55 Million EUR | 0.29% |
2014 Q2 | 634.04 Million EUR | 0.0% |
2013 Q2 | 591.47 Million EUR | 0.0% |
2013 Q4 | 667.58 Million EUR | 0.0% |
2013 FY | 667.58 Million EUR | 15.24% |
2012 Q2 | 558.6 Million EUR | 0.0% |
2012 Q1 | - EUR | -100.0% |
2012 Q4 | 579.28 Million EUR | 0.0% |
2012 FY | 579.28 Million EUR | -1.42% |
2012 Q3 | - EUR | -100.0% |
2011 Q2 | 535.43 Million EUR | 0.0% |
2011 FY | 587.6 Million EUR | 5.24% |
2011 Q4 | 587.6 Million EUR | 0.0% |
2010 Q4 | 558.33 Million EUR | 0.0% |
2010 FY | 558.33 Million EUR | 6.98% |
2010 Q2 | 492.64 Million EUR | 0.0% |
2009 Q4 | 521.93 Million EUR | 0.0% |
2009 FY | 521.93 Million EUR | 12.65% |
2008 FY | 463.34 Million EUR | 8.16% |
2007 FY | 428.39 Million EUR | 3.96% |
2006 FY | 412.05 Million EUR | -3.56% |
2005 FY | 427.25 Million EUR | 57.65% |
2004 FY | 271.01 Million EUR | 9.29% |
2003 FY | 247.97 Million EUR | 7.47% |
2002 FY | 230.72 Million EUR | 12.08% |
2001 FY | 205.86 Million EUR | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
Laboratorios Farmaceuticos Rovi, S.A. | 799.88 Million EUR | 26.214% |
Vetoquinol SA | 692.23 Million EUR | 14.739% |
Valneva SE | 469.39 Million EUR | -25.738% |
AB Science S.A. | 25.49 Million EUR | -2214.604% |
Nanobiotix S.A. | 93.89 Million EUR | -528.562% |
PHAXIAM Therapeutics S.A. | 51.3 Million EUR | -1050.332% |
Vivoryon Therapeutics N.V. | 30.82 Million EUR | -1814.434% |
BioSenic S.A. | 9.55 Million EUR | -6074.296% |
ABIVAX Société Anonyme | 327.06 Million EUR | -80.455% |
Formycon AG | 890.36 Million EUR | 33.712% |